In the secondary analysis, the much less conservative but clinically meaningful criterion of steady response (outlined to be a fifty% or more reduction in MADRS from baseline for two weeks) was used. With the patients who attained steady response, 25.eight% while in the esketamine group and 57.6% within the placebo https://gastonh555csh3.shopping-wiki.com/user